


1. A compound of the formula I



5

wherein

ring A is (C3-C8)-cycloalkanediyl or (C3-C8)-cycloalkenediyl, wherein one
10 or more carbon atoms in said (C3-C8)-cycloalkanediyl and (C3-C8)-
cycloalkenediyl groups are optionally replaced by oxygen atoms;

R is NR1R2 or OR1, (C6-C10)-aryl or (C5-C12)-heteroaryl, wherein
15 said (C5-C12)-heteroaryl group contains one, two or three identical
or different heteroatoms selected from the group consisting of N, O
and S;

R1, R2 are each independently H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or
20 (C6-C10)-aryl, wherein said (C6-C10)-aryl is optionally substituted
by F, Cl or (C1-C4)-alkyl;

R3 is (C3-C6)-cycloalkyl or (C1-C10)-alkyl, wherein each group is
optionally substituted by phenyl, pyridyl, morpholinyl or (C3-C6)-
25 cycloalkyl, and wherein said phenyl substituent is optionally
substituted by chlorine or (C1-C4)-alkyl;

X is (C1-C6)-alkanediyl, wherein one or more carbon atoms therein
are optionally replaced by oxygen atoms;

30 Y is (C1-C6)-alkanediyl, wherein one or more carbon atoms therein
are optionally replaced by oxygen atoms;

R4 is H or (C1-C4)-alkyl;

R5 is (C1-C4)-alkyl;

and pharmaceutically acceptable salts thereof.

5 2. The compound of Claim 1 wherein:

ring A is (C3-C8)-cycloalkane-1,3-diyl or (C3-C8)-cycloalkene-1,3-diyl;

R is NR1R2 or (C6-C10)-aryl;

10 R1, R2 are each independently H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or (C6-C10)-aryl, wherein said (C6-C10)-aryl group is optionally substituted by F, Cl or (C1-C4)-alkyl;

15 R3 is (C3-C6)-cycloalkyl or (C1-C8)-alkyl, wherein each group is optionally substituted by phenyl, pyridyl, morpholinyl, (C3-C6)-cycloalkyl, and wherein said phenyl substituent is optionally substituted by chlorine or methyl;

20 X is (C1-C3)-alkanediyl, wherein one carbon atom therein is optionally replaced by an oxygen atom;

Y is (C1-C3)-alkanediyl, wherein the carbon atom adjacent to ring A in said (C1-C3)-alkanediyl group is optionally replaced by an oxygen atom;

25 R4 is H;

R5 is methyl;

30 and pharmaceutically acceptable salts thereof.

3. The compound of Claim 2 wherein:

35 ring A is cyclohexane-1,3-diyl;

R is NR1R2 or phenyl;

R1 is H;

- R2 is (C1-C6)-alkyl, cyclohexyl or phenyl, wherein said phenyl group is optionally substituted by F, Cl or (C1-C4)-alkyl;
- 5 R3 is (C3-C6)-cycloalkyl or (C1-C8)-alkyl, each of which is optionally substituted by phenyl, pyridyl, morpholinyl, cyclopropyl, cyclopentyl, cyclohexyl, and wherein said phenyl substituent is optionally substituted by chlorine or methyl;
- 10 X is O-CH₂-CH₂;
- Y is OCH₂;
- 15 R4 is H;
- R5 is methyl;
- and pharmaceutically acceptable salts thereof.
- 20 4. The compound of Claim 3 wherein:
- ring A is cyclohexane-1,3-diyl;
- 25 R is NR₁R₂ or phenyl;
- R1 is H;
- 30 R2 is (C1-C4)-alkyl, cyclohexyl or phenyl, wherein said phenyl group is optionally substituted by F, Cl or methyl;
- R3 is (C3-C6)-cycloalkyl or (C1-C8)-alkyl, each of which is optionally substituted by phenyl, pyridyl, morpholinyl, cyclopropyl, cyclopentyl or cyclohexyl, and wherein said phenyl substituent is optionally substituted by chlorine or methyl;
- 35 X is O-CH₂-CH₂;
- Y is OCH₂;

R4 is H;

R5 is methyl;

5

and pharmaceutically acceptable salts thereof.

5. The compound of Claim 4 wherein the link of X and Y to ring A is cis-configured.

10

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Claim 1.

15

7. The pharmaceutical composition of Claim 8 further comprising at least one additional active ingredient.

8. The pharmaceutical composition of Claim 7 wherein said additional active ingredient has favorable effects on metabolic disturbances or disorders.

20

9. The pharmaceutical composition of Claim 7 wherein said additional active ingredient is an antidiabetic.

25

10. The pharmaceutical composition of Claim 7 wherein said additional active ingredient is a lipid modulator.

11. A method of treating disorders of fatty acid metabolism and glucose utilization comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

30

12. A method of treating disorders of insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

13. A method of treating diabetes mellitus including the prevention of the sequelae associated therewith comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.
- 5 14. A method of treating dyslipidemia and sequelae associated therewith comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.
- 10 15. A method of treating metabolic syndrome and conditions associated therewith comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.
- 15 16. A method of treating disorders of fatty acid metabolism and glucose utilization comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 in combination with at least one further active compound.
- 20 17. A method of treating disorders of insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 in combination with at least one further active compound.